As part of an ongoing cost-cutting strategy, Arrowhead Research reported last week that its Calando Pharmaceuticals subsidiary will halt clinical development of its siRNA-based cancer treatment CALAA-01 after it wraps up a phase I study of the drug, and that it has ceased all preclinical research and development efforts.

According to an Arrowhead filing with the US Securities and Exchange Commission last week, Calando will not restart any of its drug-development programs until they can be partnered or out-licensed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.